Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients.
Über uns
Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response. Replimune is pioneering the development of novel oncolytic immunotherapies. We imagine a world where cancer is a curable disease.
- Website
-
http://www.replimune.com
External link for Replimune
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- Woburn, MA
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2015
Standorte
-
Primäre
Wegbeschreibung erhalten
Woburn, MA 01801, US
Employees at Replimune
Aktualisierungen
-
Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients.
-
We are excited to be participating in the European Society for Medical Oncology (ESMO) 2024 Congress 2024 from September 13-17 in Barcelona. During the meeting, a late-breaking abstract from the IGNYTE clinical trial primary analysis will be presented during an oral session #ESMO #Melanoma Read more: https://lnkd.in/exb9TN-P
-
-
Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients.
-
Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients.
-
Today, we announced that the first patient has been randomized and dosed in the IGNYTE-3 study, our confirmatory Phase 3 trial of the investigational oncolytic immunotherapy, RP1 in combination with nivolumab in patients with advanced #melanoma. Read more: https://lnkd.in/erkStgyp
-
-
Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients.
-
Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients.
-
Replimune is looking for motivated, talented individuals to join our team as we work to transform the treatment of cancer. We are passionate about advancing and establishing a new modality and are looking for others to help us in this mission as we ultimately work to deliver significant benefit to patients.